RecruitingPhase 1NCT07618377

Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

A Phase 1 Study to Evaluate the Safety of DCC-2618 in Patients With Unresectable, Metastatic, or Recurrent Gastrointestinal Stromal Tumor (GIST) Who Are Refractory or Intolerant to at Least 3 Prior Therapies

Sponsor

Ono Pharmaceutical Co., Ltd.

Enrollment

10 participants

Start Date

Jul 7, 2026

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Stromal Tumors

Summary

To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DCC-2618 for people with gastrointestinal stromal tumors. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDCC-2618

DCC-2618 150 mg, administered orally once daily

Locations(2)

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

National Cancer Center Hospital

Tokyo, Chuo-ku, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07618377

Related Trials

Integrated Cancer Repository for Cancer Research

NCT0201269942 locations

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT071712031 location